What is ketosis‑prone diabetes (Flatbush diabetes) and what are the recommended acute and long‑term treatment strategies?

Ketosis-Prone Diabetes (Flatbush Diabetes)

Ketosis-prone diabetes (KPD), also known as Flatbush diabetes, is a distinct form of Type 2 diabetes that presents with diabetic ketoacidosis (DKA) but, unlike Type 1 diabetes, allows many patients to discontinue insulin after several months and maintain glycemic control with oral agents or diet alone due to recovery of pancreatic beta-cell function. 1

Clinical Presentation and Diagnosis

Key Diagnostic Features

• Presents with severe hyperglycemia (glucose 500-700 mg/dL) and ketoacidosis despite being a form of Type 2 diabetes 2, 3
• Negative autoantibodies (GAD65, IA-2, ZnT8, insulin antibodies) distinguishing it from autoimmune Type 1 diabetes 1, 2
• Typical patient profile: middle-aged, overweight or obese, predominantly male, most commonly affects individuals of African ancestry, Afro-Caribbean, or Hispanic descent 1, 2
• Family history of Type 2 diabetes is common 4, 2
• No precipitating cause for DKA in many cases (unprovoked DKA) 2, 5

Pathophysiology

The condition involves severe impairment of both insulin secretion and insulin action at presentation, but these improve significantly during near-normoglycemia remission to levels similar to ketosis-resistant Type 2 diabetes 1. The mechanism involves glucose desensitization and extreme insulin resistance combined with impaired insulin secretion leading to ketoacidosis 4, 3.

Acute Management

Initial Treatment of DKA

For moderate-to-severe DKA, continuous intravenous insulin infusion is the standard of care 6, 7, 8:

• Intravenous insulin protocol: Continuous IV insulin infusion is preferred unless DKA is mild 6
• Fluid replacement: Initiate aggressive fluid replacement therapy (typically 1.5 times 24-hour maintenance requirements) 6
• Electrolyte monitoring: Monitor potassium, phosphate, and other electrolytes every 2-4 hours 6
• Potassium replacement: Use 1/3 KPO4 and 2/3 KCl or K-acetate in solution 6

Mild DKA Alternative

For mild DKA, subcutaneous or intramuscular regular insulin every hour is as effective as IV administration 6:

• Priming dose: 0.4-0.6 units/kg body weight (half IV bolus, half SC/IM) 6
• Maintenance: 0.1 unit/kg regular insulin SC or IM hourly 6

Resolution Criteria

DKA is resolved when: glucose <200 mg/dL, serum bicarbonate ≥18 mEq/L, and venous pH ≥7.3 6

Transition to Subcutaneous Insulin

Critical transition step: Administer basal insulin 2-4 hours before stopping IV insulin to prevent recurrence of ketoacidosis and rebound hyperglycemia 7, 8, 9, 10. This is a common pitfall—abrupt discontinuation of IV insulin without adequate subcutaneous coverage leads to poor glycemic control 6.

Long-Term Management Strategy

The Remission Phase

The hallmark of ketosis-prone diabetes is that many patients can discontinue insulin after a few months (typically 4 weeks to several months) and maintain acceptable glycemic control 1, 2, 5:

• Initial high insulin requirement: Patients require intensive insulin therapy initially with very high doses 5
• Progressive decline: Insulin requirements progressively decline over weeks 5
• Beta-cell recovery: Pancreatic beta-cell function recovers, allowing insulin independence 4, 5, 3

Maintenance Therapy Options

After achieving remission, patients can be managed with:

1. Diet modification alone in some cases 1, 2, 11
2. Oral hypoglycemic agents (typically metformin as first-line) 1, 2, 3, 11
3. Lifestyle modifications: Dietary changes and increased physical activity 3

Monitoring and Follow-Up

Close follow-up is essential, especially in the first few months:

• Monitor for insulin independence: Assess insulin requirements every 2-4 weeks initially 5
• Watch for recurrence: No recurrence of DKA is typical during long-term follow-up if properly managed 5
• Long-term course: Clinical course resembles Type 2 diabetes rather than Type 1 diabetes 2
• Glycemic targets: Follow standard Type 2 diabetes targets (A1C, blood glucose monitoring) 1

Critical Clinical Distinctions

Differentiating from Type 1 Diabetes

Key differences from Type 1 diabetes:

• Negative autoantibodies (>90% of Type 1 patients have ≥1 antibody) 1
• Ability to discontinue insulin after initial treatment 1, 2, 11
• Older age at presentation (middle-aged vs. children/young adults) 1, 2
• Overweight/obese phenotype vs. typically lean in Type 1 1, 2

Common Pitfalls to Avoid

1. Misdiagnosis as Type 1 diabetes: Leading to unnecessary lifelong insulin therapy 1
2. Premature insulin discontinuation: Must ensure adequate beta-cell recovery before stopping insulin 5
3. Inadequate transition from IV to SC insulin: Always overlap by 2-4 hours 7, 8
4. Failure to recognize remission potential: Missing the opportunity to de-escalate therapy 2, 5

Special Considerations

Recognition is crucial because the treatment approach varies widely from conventional diabetes types 5. The condition is under-recognized and under-diagnosed globally, though increasingly reported in sub-Saharan Africans, Asian, Indian, and Hispanic populations 2. Proper identification allows for appropriate acute management followed by potential insulin independence, significantly impacting quality of life and treatment burden 3.